FDA's New One-Day Inspectional Assessments: What Mammography Facilities Should Know

Richard D. Lippert Jr. | Founder & Owner, Mammologix, Inc. | Published May 7, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Content is based on FDA's public announcements and federal regulatory materials available as of the publication date. Facilities should consult qualified legal and compliance counsel regarding their specific obligations under MQSA.

---

On May 6, 2026, the U.S. Food and Drug Administration announced a new pilot program called one-day inspectional assessments. Because the announcement mentions FDA inspection programs and "medical products," many breast imaging leaders are asking a reasonable question: Does this affect MQSA inspections?

The short answer is: not directly, based on what FDA has publicly announced so far. Routine MQSA inspections still operate under the Mammography Quality Standards Act framework. But the news still matters. It shows FDA is testing a broader, risk-based approach to oversight. For mammography facilities, the key is to know what changed, what did not, and how to stay ready.

What Did FDA Announce?

FDA said it is piloting one-day inspectional assessments. The pilot launched in April 2026 and runs through fiscal year 2026, which ends September 30, 2026. FDA called these visits shorter, focused screening assessments. They are designed to complement, not replace, standard FDA inspections.

FDA Commissioner Marty Makary, M.D., M.P.H., framed the pilot this way:

"One-day inspections can strengthen our inspectional approach by focusing our time and resources where they are most needed — enhancing our overall effectiveness. For the FDA, the ability to conduct shorter, targeted assessments allows for broader surveillance coverage, enabling the agency to assess more facilities and gather critical insights without compromising regulatory rigor. For industry, these assessments can provide timely feedback while minimizing operational disruption, particularly for lower-risk establishments."

— Marty Makary, M.D., M.P.H., FDA Commissioner

FDA says the pilot covers several inspectorates: human and animal foods, biologics, medical products, and clinical research programs. Facilities are picked using risk-based factors such as product type, prior inspection outcomes, and how the site operates.

As of late April 2026, FDA had finished about 46 one-day assessments. Most ended in No Action Indicated, or NAI, outcomes. FDA also noted that some assessments ran beyond one day when significant findings turned up.

FDA also said something that matters a great deal for the breast imaging community: the pilot does not change enforcement policy and does not apply to higher-risk or more complex facilities that need more comprehensive coverage. That single sentence is the clearest signal yet about how FDA is scoping this pilot.

What Does "One-Day Assessment" Mean?

A one-day assessment is best understood as a focused screening visit. It is not a full traditional inspection. FDA appears to be using these shorter visits to quickly check selected compliance signals.

For example, an investigator may want to confirm whether a facility's registered activities match its actual work, whether prior issues have been resolved, or whether a deeper inspection is needed.

Importantly, "one day" does not mean "limited authority." FDA stated that investigators may expand the scope or length of an assessment when warranted. The practical message is simple:

Key Concept: A one-day assessment may start small, but it can grow if FDA finds significant concerns. Facility readiness should not be tied to the planned length of a visit. It should be tied to the regulatory standard that applies, no matter how long the visit lasts.

What Does NAI Mean?

FDA classifies many inspections using three common outcome categories:

Outcome	Name	Definition
NAI	No Action Indicated	No objectionable conditions or practices were found during the inspection or assessment.
VAI	Voluntary Action Indicated	Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI	Official Action Indicated	Regulatory and/or administrative actions are recommended.

When FDA says most one-day assessments ended in NAI, that means most assessed facilities had no objectionable findings within the scope of those visits. It does not mean every part of each facility was fully reviewed.

Is MQSA Included in This New Pilot?

FDA's public announcement does not mention MQSA, mammography facilities, or annual MQSA inspections. That silence is meaningful.

FDA says the pilot includes "medical products" and "clinical research programs." But it does not say that annual mammography facility inspections under MQSA are being changed, shortened, replaced, or folded into this pilot.

At the same time, FDA's Office of Medical Device and Radiological Health Inspectorate oversees medical devices and radiological health products. Mammography oversight sits within this broader inspectional ecosystem, even though MQSA inspections operate under their own statutory framework.

The safest reading of the public record is this:

Bottom Line: Routine MQSA inspections are not part of this one-day assessment pilot. FDA also said the pilot does not apply to higher-risk or more complex facilities. Even so, the broader move toward targeted, risk-based oversight may shape how FDA evaluates inspectional strategy across programs over time.

Why MQSA Is Different from the Standard FDA Inspection Database

One reason for confusion is FDA's own inspection classification database. FDA says the database includes final classifications such as NAI, VAI, and OAI for many inspections. FDA also states clearly that mammography facility inspections are not included in that database.

That gap is important, but it should not be misread.

It does not mean mammography facilities are outside FDA oversight. It means routine mammography facility inspections are handled and reported in their own way, separate from many standard FDA inspections.

MQSA inspections have a separate regulatory and reporting structure. Their absence from the standard inspection classification database does not mean FDA has stopped inspecting mammography facilities.

What Remains Unchanged for Mammography Facilities?

For mammography facilities, the core MQSA duties are still in place.

FDA's MQSA inspection resources state that each mammography facility in the United States, except those of the Department of Veterans Affairs, must:

• Meet federal quality standards;
• Be accredited by an FDA-approved accreditation body;
• Be certified to perform mammography;
• Have an annual medical physicist survey;
• Undergo an annual inspection by an MQSA inspector;
• Pay required inspection fees; and
• Correct any deficiencies that are found.

Federal mammography rules are codified in 21 CFR Part 900. These rules carry out the Mammography Quality Standards Act and apply to facilities under U.S. regulatory jurisdiction that provide mammography services, with an exception for the Department of Veterans Affairs.

FDA also describes the annual MQSA inspection as a visit by an MQSA-certified inspector who checks a facility's compliance with MQSA quality standards. The annual inspection covers equipment performance, quality assurance records, quality control records and tests, technologist tests, the medical physicist's annual survey report, mammography equipment evaluations where applicable, personnel qualification records, mammography medical reports and lay summaries, and medical audit and outcome analysis records.

For now, mammography facilities should assume the same simple thing they have always assumed:

The annual MQSA inspection requirement remains unchanged.

Why This Announcement Still Matters to Breast Imaging Leaders

Even if routine MQSA inspections are not part of the pilot, this announcement is still relevant for breast imaging administrators, lead interpreting physicians, quality managers, medical physicists, and compliance teams.

FDA Associate Commissioner for Inspections and Investigations Elizabeth Miller, Pharm.D., explained how FDA plans to use the data the pilot creates:

"We are closely analyzing the operational and compliance data from these assessments — including trends in outcomes, risk signals, and investigator feedback — to determine how this approach can enhance our broader inspectional strategy."

— Elizabeth Miller, Pharm.D., FDA Associate Commissioner for Inspections and Investigations

FDA is clearly leaning into risk-based oversight, more efficient use of inspection resources, and better data-driven targeting. FDA also said data from these assessments — recurring compliance themes, facility-specific risk scores, and gaps between registered and actual operations — can be used to better target future oversight. These themes match the way regulatory oversight has been moving across healthcare and medical products.

For breast imaging, this matters because mammography facilities already work in a highly structured quality environment. Facilities must keep records on personnel qualifications, equipment quality control, medical physicist surveys, medical audits, mammography reports, patient lay summaries, corrective actions, and accreditation.

A shorter, more focused oversight model in other FDA areas reinforces a practical lesson for MQSA facilities:

Inspection readiness should be continuous, not seasonal.

What Should Mammography Facilities Do Now?

Mammography facilities do not need to treat the FDA announcement as a change to MQSA inspection frequency or scope. There is no public sign that annual MQSA inspections are being replaced by the one-day assessment pilot.

Facilities should, however, use the news as a reminder to keep core compliance areas current and well-organized. Recommended focus areas include the following.

• MQSA certificate and accreditation status. Confirm the facility's certificate is current, displayed where mammography patients can see it, and consistent with actual operations.
• Personnel qualifications. Verify that interpreting physicians, radiologic technologists, and medical physicists meet MQSA rules and that documentation is current and easy to find.
• Medical physicist survey records. Make sure annual survey records are complete, accessible, and reviewed by facility leadership.
• Quality control records. Confirm that required QC tests are run, documented, reviewed, and corrected when needed.
• Mammography reports and lay summaries. Confirm that reporting and patient notification meet current MQSA rules, including the breast density communication rules that became enforceable on September 10, 2024.
• Medical audit and outcome analysis. Keep audit records current and make sure the interpreting physician audit process is active, accurate, and easy to retrieve on request.
• Corrective action documentation. When problems show up, document what was found, what was fixed, who was responsible, and when the fix was completed.
• Operational accuracy. Make sure facility, equipment, contact, and service information actually match what is happening in the facility today.

---

The Key Takeaway

FDA's one-day inspectional assessment pilot is a new oversight tool. It helps the agency run shorter, more targeted assessments across selected FDA-regulated areas. The pilot launched in April 2026 and runs through fiscal year 2026.

For mammography facilities, the news should not be read as a change to MQSA annual inspection rules. FDA has not said that MQSA inspections are part of the pilot. FDA has also said the pilot does not apply to higher-risk or more complex facilities. Routine MQSA inspections still operate under the MQSA framework, which calls for annual inspections, accreditation, certification, quality standards, medical physicist surveys, and the correction of any deficiencies.

The practical message is simple: keep MQSA documentation current, make sure actual operations match official records, and treat every regulatory interaction as important — even if it is short or focused.

---

References

1. U.S. Food and Drug Administration. FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight. Press Announcement. May 6, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-one-day-inspectional-assessments-strengthen-and-expand-oversight
2. U.S. Food and Drug Administration. Inspection Classifications. Inspections, Compliance, Enforcement, and Criminal Investigations. Content current as of April 18, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/inspection-classifications
3. U.S. Food and Drug Administration. Inspection Classification Database. Inspections, Compliance, Enforcement, and Criminal Investigations. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classification-database
4. U.S. Food and Drug Administration. Office of Medical Device and Radiological Health Inspectorate (OMDRHI). Office of Inspections and Investigations. Content current as of February 3, 2026. https://www.fda.gov/about-fda/oii-inspectorates/office-medical-device-and-radiological-health-inspectorate-omdrhi
5. U.S. Food and Drug Administration. MQSA Inspection Resources. Mammography Quality Standards Act and MQSA Program. Content current as of March 28, 2024. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/mqsa-inspection-resources
6. U.S. Food and Drug Administration. The Annual MQSA Inspection: What Facilities Can Do To Help. MQSA Insights. September 9, 2024. https://www.fda.gov/radiation-emitting-products/mqsa-insights/annual-mqsa-inspection-what-facilities-can-do-help
7. U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
8. Federal Register. Mammography Quality Standards Act. Final Rule. Published March 10, 2023. https://www.federalregister.gov/documents/2023/03/10/2023-04550/mammography-quality-standards-act
9. Electronic Code of Federal Regulations. 21 CFR Part 900 — Mammography. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-I/part-900
10. Electronic Code of Federal Regulations. 21 CFR Part 900, Subpart B — Quality Standards and Certification. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-I/part-900/subpart-B/
11. Electronic Code of Federal Regulations. 21 CFR 900.12 — Quality Standards. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-I/part-900/subpart-B/section-900.12